Home > Cardiology > Pilot trial shows potential benefit of stem-cell therapy in microvascular dysfunction

Pilot trial shows potential benefit of stem-cell therapy in microvascular dysfunction


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
Circulation: Cardiovascular Interventions
Reuters Health - 02/02/2022 - A single infusion of autologous CD34-positive stem cells was associated with improved coronary flow reserve and angina symptoms in patients with microvascular dysfunction in a pilot study. About 50% to 70% of patients with ischemia with non-obstructive coronary-artery disease (INOCA) have evidence of microvascular dysfunction, which is associated with an increased risk for major cardiovascular events, Dr. Timothy Henry of Christ Hospital in Cincinnati, Ohio, and colleagues note in Circulation: Cardiovascular Interventions. Autologous CD34+ cells have "potent" angiogenic capabilities and studies in patients with refractory angina have established the feasibility and potential benefit of autologous CD34+ cells administered directly into the myocardium. The current trial enrolled 20 patients with INOCA, persistent angina and documented coronary microvascular dysfunction defined by a coronary flow reserve (CFR) of 2.5 or less in the ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on